77 related articles for article (PubMed ID: 23870706)
1. Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients.
Sicras Mainar A; Roldán Suárez C; Font Ramos B; Navarro Artieda R; Ibáñez Nolla J
Rev Clin Esp (Barc); 2013 Nov; 213(8):377-84. PubMed ID: 23870706
[TBL] [Abstract][Full Text] [Related]
2. [Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: a population study].
Sicras-Mainar A; Font-Ramos B; Roldán-Suárez C; Navarro-Artieda R; Ibáñez-Nolla J
Endocrinol Nutr; 2013 Dec; 60(10):557-69. PubMed ID: 24008167
[TBL] [Abstract][Full Text] [Related]
3. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
Sicras-Mainar A; Navarro-Artieda R
Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome.
Sicras-Mainar A; Navarro-Artieda R
Diabetes Technol Ther; 2014 Nov; 16(11):722-7. PubMed ID: 25089916
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients.
Sicras-Mainar A; Navarro-Artieda R
Diabetes Metab J; 2015 Feb; 39(1):74-81. PubMed ID: 25729716
[TBL] [Abstract][Full Text] [Related]
6. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
8. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
9. Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly.
Sicras-Mainar A; Navarro-Artieda R
Drug Des Devel Ther; 2014; 8():811-8. PubMed ID: 24970999
[TBL] [Abstract][Full Text] [Related]
10. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study.
Penfornis A; Bourdel-Marchasson I; Quere S; Dejager S
Diabetes Metab; 2012 Dec; 38(6):550-7. PubMed ID: 22996038
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
Mintz ML; Minervini G
Curr Med Res Opin; 2014 May; 30(5):761-70. PubMed ID: 24397584
[TBL] [Abstract][Full Text] [Related]
14. A comparison of costs for four oral antidiabetic regimens within a managed care population.
Stockl K; Vanderplas AM; Nicklasson L
Manag Care Interface; 2003 Jul; 16(7):31-6. PubMed ID: 12908215
[TBL] [Abstract][Full Text] [Related]
15. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization.
Genovese S; Tedeschi D
Adv Ther; 2013 Feb; 30(2):152-64. PubMed ID: 23430354
[TBL] [Abstract][Full Text] [Related]
16. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
17. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
Barner JC
Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
[TBL] [Abstract][Full Text] [Related]
18. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
19. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
Ramsdell JW; Grossman JA; Stephens JM; Botteman MF; Arocho R
Am J Manag Care; 1999 Aug; 5(8):1007-24. PubMed ID: 10558125
[TBL] [Abstract][Full Text] [Related]
20. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Hansen RA; Farley JF; Droege M; Maciejewski ML
Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
